ArticleOncogenesis2026
Stanniocalcin 1 contributes to glioma stem cells phenotypic plasticity through NOTCH1/STAT3/GFPT2 axis.
Article in Oncogenesis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Glioma stem cells (GSCs) are key drivers of glioblastoma (GBM) tumorigenesis, invasion, therapy resistance, and recurrence and exhibit remarkable phenotypic plasticity. Stanniocalcin 1 (STC1) has been implicated in tumor progression and cancer stemness; however, its role and the molecular mechanisms through which it shapes GSC plasticity and malignant traits remain poorly understood. Here, transcriptomic RNA sequencing identified STC1 as a malignancy-associated gene enriched in GBM and mesenchymal (MES)-like GSCs. Comprehensive bioinformatic analyses further validated that STC1 was highly expressed in MES-like GBM/GSCs and closely associated with poor patient survival. Functional studies revealed that STC1 promoted multiple malignant properties of GSCs, including self-renewal, migration, invasion, tumorigenicity, and cellular plasticity. Conversely, STC1 silencing attenuated these effects. Mechanistically, STC1 activated the NOTCH1/STAT3 signaling cascade, leading to transcriptional upregulation of GFPT2, a key rate-limiting enzyme of the hexosamine biosynthetic pathway. This subsequently enhanced global O-GlcNAcylation, including modification of P65, thereby facilitating GSC plasticity and malignant progression. Genetic and pharmacological interventions targeting this signaling axis effectively mitigated the oncogenic effects driven by STC1. In conclusion, our study reveals that STC1 is a key regulator of GSC phenotypic plasticity and aggressiveness through the NOTCH1/STAT3/GFPT2/O-GlcNAcylation pathway. These results provide new mechanistic insights into GBM progression and suggest that targeting STC1-associated signaling networks may represent a potential therapeutic strategy for GBM.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.